Table 1 Characteristics of NPC patients with INN
Characteristic | Original data set (n = 53) | Matched data set n = 212) | p |
|---|---|---|---|
Gender | Â | Â | 0.511 |
 Male | 39 (73.6) | 165 (77.8) |  |
 Female | 14 (26.4) | 47 (22.2) |  |
Age (y) | Â | Â | 0.442 |
 Median; Range | 55; 17–78 | 55; 18–83 |  |
Comorbidity | Â | Â | Â |
 Anemia | 2 (3.8) | – |  |
 Hypertension | 10 (18.9) | – |  |
 Diabetes | 7 (13.2) | – |  |
Pathology | Â | Â | Â |
Non-keratinizing undifferentiated carcinoma | 34 (64.2) | 122 (57.5) | Â |
Non-keratinizing differentiated carcinoma | 18 (34) | 89 (42) | Â |
 Keratinizing carcinoma | 1 (1.9) | 1 (0.5) |  |
Necrosis before treatment | Â | Â | Â |
 Yes | 7 (13.2) | – |  |
 No | 46 (86.8) | – |  |
HGB before treatment | Â | Â | 0.139 |
 Median; Range | 143 (82–181) | 142;91–182 |  |
Pseudomembrane during radiation | Â | Â | Â |
 Yes | 38 (71.7) | – |  |
 No | 15 (28.3) | – |  |
T staging | Â | Â | 0.93 |
 T1 | 3 (5.7) | 16 (7.5) |  |
 T2 | 5 (9.4) | 17 (8.0) |  |
 T3 | 18 (34) | 77 (36.3) |  |
 T4 | 27 (50.9) | 102 (48.1) |  |
N staging | Â | Â | 0.911 |
 N0 | 9 (17.0) | 35 (16.5) |  |
 N1 | 17 (32.1) | 73 (34.4) |  |
 N2 | 20 (37.7) | 83 (39.2) |  |
 N3 | 7 (13.2) | 21 (9.9) |  |
Stage | Â | Â | Â |
 I | 0 | 3 (1.4) |  |
 II | 6 (11.3) | 7 (3.3) |  |
 III | 16 (30.2) | 82 (38.7) |  |
 IV | 31 (58.5) | 120 (56.6) |  |
Chemotherapy | Â | Â | Â |
 No | 16 (30.2) | 68 (32.1) |  |
 Neoadjuvant | 6 (11.3) | 30 (14.2) |  |
 Concurrent | 34 (64.2) | 106 (50.0) |  |
 Adjuvant | 4 (7.5) | 8 (3.8) |  |
Target therapy | Â | Â | Â |
 Yes | 10 (18.9) | 66 (31.1) |  |
 No | 43 (81.1) | 146 (68.9) |  |
Local boost | Â | Â | Â |
 Yes | 8 (15.1) | 5 (2.4) |  |
 No | 45 (84.9) | 207 (97.6) |  |
INN stage | Â | Â | Â |
 Early | 32 (60.4) | – |  |
 Middle | 21 (39.6) | – |  |
 Serve | 0 | – |  |